Congress Park Capital LLC Clovis Oncology, Inc. Transaction History

Congress Park Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 02, 2019	SELL	$12.81 - $25.67 $161,726 - $324,083	-12,625 Closed	0 $0
Q1 2019 Apr 18, 2019	SELL	$17.66 - $30.28 $89,183 - $152,914	-5,050 Reduced 28.57%	12,625 $313,000
Q4 2018 Feb 06, 2019	BUY	$11.63 - $32.67 $6,163 - $17,315	530 Added 3.09%	17,675 $317,000
Q3 2018 Oct 29, 2018	BUY	$29.37 - $49.48 $79,299 - $133,596	2,700 Added 18.69%	17,145 $504,000
Q2 2018 Aug 06, 2018	BUY	$42.06 - $62.4 $413,449 - $613,392	9,830 Added 213.0%	14,445 $657,000
Q1 2018 Apr 17, 2018	BUY	$50.12 - $67.72 $231,303 - $312,527	4,615 New	4,615 $244,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Congress Park Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Congress Park Capital LLC with notifications on news.